Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement
CBD Blunted Neuroinflammation Sustained By Astrocytes Through PPARγ Selective Activation In Vitro And In Vivo
The first set of experiments was aimed at assessing the role of CBD (10−9–10−7 M) on the release of inflammatory mediators induced by Aβ challenge (1 µg/ml). Treatment with Aβ for 24 h resulted in a significant increase of NO. CBD concentration dependently antagonized the enhanced release of these pro-inflammatory molecules, and blockade of PPARγ with GW9662 (PPARγ antagonist, 9 nM) reversed this effect.
Effect of CBD On The Release Of Inflammatory Mediators By In Vitro Cultured Astrocytes.
In astrocyte lysates, made 24 h after treatment, the parallel expression of iNOS, GFAP, and S100B was evaluated. CBD, in a concentration dependent manner, attenuated the Aβ-induced protein up-regulation and such an effect was related to the inhibition of NFκB. In fact, in astrocyte lysates prepared 3 h after treatment, CBD down-regulated the expression of both p50 and p65. The reduction of reactive gliosis displayed by CBD was to be considered as the result of a selective PPARγ dependent NFκB inhibition.
Results from the present study prove the selective involvement of PPARγ in the anti-inflammatory and neuroprotective effects of CBD here observed either in vitro and in vivo. In addition, CBD significantly promoted neurogenesis in Aβ injured rat hippocampi, much expanding its already wide spectrum of beneficial actions exerted in AD models, a non negligible effect, due to its capability to activate PPARγ.
CBD was already reported to exert a marked anti-inflammatory effect through the A2A and 5HT1A receptors , , as well as to improve brain function . In addition, it has been already demonstrated that CBD markedly downregulate reactive gliosis by reducing pro-inflammatory molecules and cytokine release that strongly occurs in Aβ neurotoxicity. This activity was linked to its ability to act as a potent inhibitor of NFκB activation induced by Aβ challenge . The present findings, confirming the formerly obtained results and extending our knowledge about CBD pharmacology, indicate that a selective PPARγ activation occurs upstream to CBD-mediated NFκB inhibition. Such activation appears to be responsible for a large plethora of CBD effects. Indeed, the interaction of CBD at the PPARγ site results in a profound inhibition of reactive gliosis as showed by the reduction of both GFAP and S100B protein expression together with a marked decline of pro-inflammatory molecules and cytokine release observed in Aβ challenged astrocytes.
Materials and Methods
In Vivo Treatments
After full recovery from stereotaxic surgery, depending upon the experimental protocol design, rats were i.p. administered for 15 days with: CBD 10 mg/kg, MK886 10 mg/kg, and GW9662 1 mg/kg. All coumpounds were dissolved in PEG/Tween80/saline (Sigma Aldrich), 5∶5∶90. Control rats were i.p. given an equivalent volume of the proper vehicle. All drug solutions were freshly prepared on the day of the experiment. The drug concentrations were chosen according to their IC50, and on the basis of the results of our preliminary experiments. Rats to be subjected to immunoblotting experiments underwent deep anaesthesia and sacrificed by decapitation. Their brains were extracted and ipsilateral hippocampi to injection site were dissected and frozen in liquid N2 before the tissue lysis for immunoblot analysis and/or ELISA assay. Rats to be subjected to morphological analysis were sacrificed through transcardiac perfusion with paraformaldehyde 4%. The extracted brains were post-fixed overnight with the same fixative, protected with 30% sucrose, and frozen using 2-methylbutane.
Gating the Polarity of Endocannabinoid-Mediated Synaptic Plasticity by Nitric Oxide in the Spinal Locomotor Network
Materials And Methods
All experiments were performed on in vitro preparations of the isolated, intact spinal cord from adult lampreys (Lampetra fluviatilis) of either sex. All protocols were approved by the Animal Research Ethical Committee, Stockholm. Lampreys were anesthetized with MS-222 (100 mg/L; Sigma-Aldrich) and eviscerated, and the lateral muscle walls were removed. The spinal cord and notochord were dissected and pinned in a cooled (8–12°C) Sylgard-lined experimental chamber continuously perfused with physiological solution. The control solution was composed of the following (in mm): 138 NaCl, 2.1 KCl, 1.8 CaCl2, 1.2 MgCl2, 4 glucose, and 2 HEPES, bubbled with O2 and pH adjusted to 7.4. Fictive swimming activity was induced by adding 50–100 μm NMDA to the physiological solution. Alternating locomotor burst activity was recorded by en passant glass suction electrodes placed on two opposing ventral roots at their exits from the spinal cord. After perfusion of NMDA, the locomotor burst frequency increased gradually over time and reached a stable level after 3–4 h. Pharmacological reagents were normally added only after the burst frequency had been stable for at least 1 h. Two minute recordings of ventral root activity were sampled every 5 min. The cycle duration was measured and averaged from 100 to 200 consecutive cycles. The cycle duration was defined as the time interval between the onsets of two consecutive bursts, and the burst frequency was calculated as the inverse of the averaged cycle duration. To examine the changes in midcycle reciprocal inhibition during locomotion, intracellular recordings were made from motoneurons (MNs) and rhythmically active unidentified interneurons with 3 m potassium acetate-filled thin-walled glass microelectrodes with a resistance of 15–30 MΩ. MNs were identified by recording their axonal action potentials in a one-to-one manner from the corresponding ventral root through the extracellular suction electrode. All MNs recorded during fictive locomotion received phasic excitation alternating with phasic inhibition. The concurrent recordings of the locomotor frequency and of the activity of MNs allowed us to correlate changes in the synaptic amplitude with changes in locomotor frequency. Two minute recordings of intracellular and extracellular activity were sampled every 5 min. The spikes were removed using a digital low-pass filter (30 Hz), and the synaptic input was averaged from 100 to 200 cycles; their duration was normalized and aligned according to the membrane potential of the recorded neurons. The peak-to-trough amplitude of the locomotor-related synaptic input was measured and monitored in control and in the presence of different pharmacological agents.
New perspectives in neuroprotection and anti-inflammatory therapy of this Parkinson’s neurodegenerative disease
We investigated the relationship of CB1R and D2/D3 receptor densities in PD human brains by means of receptor autoradiography. [125I]SD7015, a novel CB1R agonist,  and [3H]raclopride, a dopamine D2/D3 receptor antagonist , were applied as radioligands.
CB1R densities in putamen, nucleus caudatus and frontal cortex samples seem to be unchanged in PD while in contrast, dopamine D2/D3 receptor density in PD putamen and nucleus caudatus decreases. The latter is in line with previous findings, namely this decrease of D2/D3 receptor density in PD putamen and nucleus caudatus could be the consequence of longterm antiparkinsonian treatment. It is generally agreed that dopaminergic denervation leads to striatal D2 dopamine receptor up-regulation as postsynaptic compensatory mechanism in response to deficiencies in synaptic dopamine signaling [1,3,24,67,85]. Treatment of PD patients with dopaminergic drugs returns the striatal dopamine D2 receptor expression to near normal levels [1,67,98]. Frontal cortex samples presented no difference between the subject cohorts.
The CB system in experimental PD models and PD patients has been extensively studied, yet with contradictory conclusions. In rat Parkinson models (reserpine treatment or 6-OHDA-lesion models) an increase in endogenous endocannabinoid levels was observed in the striatum [19,26,38,68] as it was also observed in the CNS of 16 untreated PD patients . Other authors found significantly altered CB1R mRNA expression in animal models of PD or in postmortem human PD brain specimens. [50,89,95,107]. Finally, changes in CB1R binding sites [30,63,80] and activation of GTP-binding proteins in the basal ganglia of PD patients and of MPTP-treated marmosets were also reported . On the other hand, using the 6-OHDA rat model Romero et al.  did not find significant changes in CB1 receptor binding, measured by [3H]WIN-55,212,2 autoradiography, or in the activation of signal transduction mechanisms, measured by WIN-55,212,2-stimulated [35S]GTPgammaS binding autoradiography, between the lesioned and non-lesioned sides at the level of the lateral caudate-putamen, globus pallidus and substantia nigra.
In the present study we did not find changes in CB1R densities in the striatum and frontal cortex of PD subjects. One of the explanations for the unaltered CB1R density found by us could be the unchanged density of high affinity CB1Rs in the investigated PD brain regions [63,89]. This may be possible due to the presence of the large reserve of CB1Rs and their likely inter-conversion between low and high affinity states [4,94]. Due to low sample size results are only suggestive in the aspect of an intact CB1R density. This statement requires further justification in the future by studies using more specimens and performing the detailed investigation of this problem.
On the other hand, functional relationship have been reported between CB1Rs and both dopamine D1 and D2 receptors [33,34,46,51,60,63,70,75,89, 99]. For instance, Giuffrida et al.  proved that striatal administration of D2 agonist results in release of endocannabinoids. Furthermore, activation of CB1 or dopamine D2 receptors alone resulted in inhibition of cAMP accumulation whereas simultaneous activation of both receptors increased cAMP levels . Kreitzer and Malenka  reported in animal models of Parkinson’s disease that DA depletion blocked the generation of endocannabinoid-mediated long-term depression (eCB-LTD) in indirect striatal pathway but administration of dopamine D2 receptor agonist together with inhibitors of endocannabinoid degradation rescued indirect-pathway eCB-LTDs and in vivo reduced parkinsonian motor deficits. Dopamine receptor antagonists inhibited cannabinoid induced striatal mitogen activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) activation .
Administration of CB1R agonists increased dopamine turnover and release [15,31,32,87], excited dopaminergic neurons in the ventral tegmental area and substantia nigra , decreased the tremor associated with overactivity of the subthalamic nucleus and improved motor impairment [2,72,92], at the same time a CB1 antagonist (rimonabant) alleviated hypokinesia in animal models of Parkinson’s disease [37,54], probably effecting on the lateral globus pallidus. It has been demonstrated that glutamatergic and GABAergic terminals strongly express CB1Rs and CB1R agonists significantly inhibited glutamate and GABA release, however, cannabinoids in vitro, directly did not affect the release of dopamine [29,58,97]. Yin et al.  observed that presynaptic reduction in glutamate release was the consequence of a retrograde signal through eCBs; this eCB synthesis and release from the postsynaptic cell results from cooperating, convergent glutamate and dopamine inputs. A potential indirect dopamine–CB1R interaction through the cannabinoid induced regulation of the upper mentioned neurotransmitters (GABA, glutamate) of striatal neuronal pathways could be the basis of cannabinoid effect on motor activity. However, the findings of  that dopaminergic cells also express CB1R as well as observations about functional interactions between CB1Rs and both dopamine D1 and D2 receptors [33,34,46,51,60,63,70,74,89,99]. could contribute to the upper mentioned effect as well. Due to the complexity of this cannabinoid–dopamine receptor conundrum further researches are required with well designed study protocols. Although our results base on relatively small sample size, they refer to the presence of an apparently intact CB1 receptor population may be usable in PD therapy, even in advanced PD.
On the other hand, it is accepted that classical neuroinflammatory diseases such as multiple sclerosis present aspects of neurodegeneration, while classical degenerative disorders such as Alzheimer’s disease, Parkinson’s disease are demonstrably affected by inflammation . In CNS CB1 receptors exist in all types of neural cells, in astrocytes [9,91], microglia [100,103], and oligodendrocytes  whereas CB2receptors are expressed on cells of immune system and microglia . Studies report neuroprotective [43,71,88] and anti-inflammatory effects through CB receptors [13,55,56,57,81,102]; CBs protected against dopaminergic cell death, as well . Thus CB1 and CB2 receptors could provide substrate for neuroprotective and anti-inflammatory actions of cannabinoids in neurodegenerative diseases, however, the effects through CB1Rs are more relevant to neuroprotection, whereas CB2Rs modulate the immune response primarily, although a potential overlap as well as non CB1/CB2-mediated mechanisms may exist .
In this study we used PD putamen, nucleus caudatus, medial frontal gyrus samples in order to correlate CB1 receptor density with dopamine D2/D3 receptor density. Our results refer to an unchanged CB1R and decreased dopamine D2/D3 receptor density in nucleus caudatus and putamen of PD patients whereas medial frontal gyrus sections did not show any alteration. Our data suggest that in case of long-term l-DOPA treatment and long disease progression CB1R density does not fall under control levels, although, dopamine D2/D3 receptor density is significantly decreased. Various explanations could exist: (1) neurodegeneration induced affinity or sensitivity increase of ‘reserve’ CB1Rs could compensate CB1R density changes, (2) reactive changes of CB system could go along with PD progression, until more effective compensatory mechanisms come into action, (3) despite the decreased density, dopamine D2receptor signal transduction seems functionally intact ) and possible physiological interactions with CB1 receptors could be maintained even in later stages of PD, which could result in unchanged CB1R density; however, functional receptor crosstalks between these receptor types are, yet, unequivocally unproven. Nevertheless the combination up to various degree of the aforementioned or other, yet, unknown mechanisms is the most probable phenomenon.
Multiple Functions of Endocannabinoid Signaling in the Brain
Predator-prey competition is a major driving force behind evolution. For example, most plants developed a dedicated repertoire of chemical molecules to distract consumption. These allelochemicals often mimic or perturb endogenous signaling pathways in the nervous system, thereby becoming behaviorally effective. It seems that the underlying evolutionary processes were robust enough to invent receptor agonists or antagonists and even allosteric activators or inhibitors of enzymes with excellent potency and affinity. This natural treasure trove served traditional medicine for several thousand years and still remains a major frontier for drug discovery (Li and Vederas, 2009). Moreover, neuroscience research has also greatly profited from deciphering the mechanisms by which these plant products are behaviorally active, paving the way for the discovery of several endogenous signaling systems primarily active in the brain (Prisinzano, 2009).
A prime example is the cannabis plant (Cannabis sativa L.) and the discovery of the endocannabinoid system in animals. Cannabis plants produce a unique mixture of chemical constituents, the most famous products being the C21 terpenophenolic compounds, which are collectively called phytocannabinoids. Detailed chemical analysis have identified about 70 molecular species of phytocannabinoids (ElSohly and Slade, 2005), but unquestionably, one molecule and its discovery stands out. Intriguingly, this aromatic terpenoid has been more famous (or infamous, as one wishes) among the public than among neuroscientists until very recently. This compound called (−)-Δ9-tetrahydrocannabinol (Δ9-THC) was isolated from confiscated hashish by Yechiel Gaoni and Raphael Mechoulam (Fig. 1A-B) (Gaoni and Mechoulam, 1964), and was shown to account for the psychotropic effects of cannabis preparations in rhesus monkeys (Mechoulam et al., 1970). This seminal discovery transformed cannabinoid research from an anecdote-based practice into an evidence-based modern research field. The use of the chemically defined Δ9-THC molecule made it possible to obtain qualitatively and quantitatively reproducible pharmacological, physiological or behavioral data, which then helped to uncover the neurobiological substrates of psychoactive effects of cannabis.
A Tribute To The Discoveries Unraveling The Endocannabinoid System
The second major breakthrough in cannabinoid research provided answer to the conceptual question of why our brain reacts to cannabis. Using [3H]-CP55,940, a potent radioactively-labeled synthetic cannabinoid, Bill Devane, Allyn Howlett and their colleagues obtained the first unequivocal evidence for the presence of a specific cannabinoid receptor, which inhibits adenylate cyclase via Gi-protein signaling in the brain (Fig. 1C-D) (Devane et al., 1988; Bidaut-Russell et al., 1990). This discovery is also considered as the first direct evidence for existence of the endocannabinoid system. The subsequent qualitative and quantitative radioligand binding studies quickly revealed the distribution of cannabinoid receptors in the brain (Fig 1E) (Herkenham et al., 1990). First, lesion experiments showed that the vast majority of cannabinoid binding sites in the brain are on neurons, and most likely on their axonal bundles (Herkenham et al., 1991). Second, the quantitative distribution pattern fitted well with the brain regions underlying the behavioral effects of cannabis. Third, this pattern was remarkably similar across species indicating a conserved physiological function for cannabinoid receptors. Finally, and most importantly, the density of cannabinoid receptors in the brain was comparable to the levels of glutamate, GABA or striatal dopamine receptors (Herkenham et al., 1990). Thus, these observations collectively predicted in advance that cannabinoid receptors are as ubiquitous components of chemical synapses as conventional neurotransmitter receptors.
This period was the golden age for the cloning of G-protein-coupled receptors, thus, the molecular identification of the first cannabinoid receptor has followed very soon (Matsuda et al. 1990). The CB1cannabinoid receptor indeed turned out to be a class A G-protein-coupled receptor, and has a notably similar sequence (97-99% amino acid sequence identity) across mammalian species, supporting once again a phylogenetically conserved function for CB1. In situ hybridization confirmed neuronal expression and revealed a heterogeneous distribution pattern largely corresponding to the ligand binding sites (Matsuda et al. 1990). With the help of significant homology (44% at the amino acid level), a second cannabinoid receptor was also discovered thereafter (Munro et al., 1993). These two receptors originated from a common ancestor, and it is now fairly safe to conclude that a third, phylogenetically closely related third cannabinoid receptor is unlikely to be found (Pertwee et al., 2010).
Compelling evidence shows that CB1 receptors are the major neurobiological substrates for Δ9-THC effects on the human brain. The acute psychological consequences of marijuana smoking such as the subjective “high” experience was efficiently blocked by pretreatment with the CB1 antagonist, rimonabant in healthy human subjects (Huestis et al., 2001). Moreover, the development of novel inverse agonist radioligands for positron emission tomography now allows the monitoring of CB1 receptor availability in the living human brain (Burns et al., 2007) (Fig. 1F). The tremendous potential of this new approach is reflected by the emerging data showing robust changes in CB1 receptor availability in patients with Huntington disease, or temporal lobe epilepsy (Van Laere et al., 2010; Goffin et al., 2011), or by the demonstration of cortex-specific downregulation of CB1 availability in chronic cannabis smokers, which is a long-suspected mechanism of cannabis tolerance (Hirvonen et al., 2011).
While CB1 receptors are considered as primarily neuronal receptors, CB2 receptors are highly expressed in the spleen and regarded as the predominant cannabinoid receptor of the immune system. This somewhat simplified concept has been ideal to provide a framework for the potential therapeutic exploitation of the endocannabinoid system; one particularly exciting example is that the beneficial effects of Δ9-THC in multiple sclerosis is mediated by neuronal CB1 receptors and by CB2 receptors on autoreactive T cells in tandem (Maresz et al., 2007). However, accumulating data also support important physiological and pathophysiological functions for peripheral CB1 receptors (Kunos et al., 2009), whereas central effects of CB2 receptors are well-documented in emesis regulation or in rewarding effects of cocaine (Van Sickle et al., 2005; Xi et al., 2011).
The discovery of cannabinoid receptors initiated an immediate quest for their endogenous ligands, the so-called endocannabinoids. Because of the lipophilic nature of phytocannabinoids, Devane, Mechoulam and their colleagues argued that lipid-soluble fractions of the brain should contain the putative endocannabinoid molecule, which finally led them to its chemical identification (Fig. 1G-H) (Devane et al., 1992). This compound, N-arachidonoylethanolamide was termed anandamide based on the Sanskrit word “ananda” meaning “inner bliss”. This name reflects a good foresight, because anandamide plasma levels are significantly reduced in patients with major depression (Hill et al., 2009), and blockade of anandamide hydrolysis exerts robust anti-depressant-like effects (Gobbi et al., 2005). Anandamide turned out to be a partial agonist of the two cannabinoid receptors, which is unusual for an endogenous natural ligand, and it is found at low concentrations (pmol/g tissue) in the brain (Pertwee et al., 2010). Because its pharmacological activity did not fully recapitulate the behavioral effects of Δ9-THC (Smith et al., 1994), the existence of a second endocannabinoid was postulated, and soon identified as 2-arachidonoylglycerol(2-AG) (Fig. 1I-J) (Mechoulam et al., 1995; Sugiura et al., 1995). 2-AG is a full agonist at both CB1 and CB2 receptors and it is present at much higher levels (nmol/g tissue) in the brain (Stella et al., 1997). With the discovery of anandamide, 2-AG and the cannabinoid receptors, the “grass route” has gloriously ended after 3 decades, and gave the green light to neuroscientists to continue with hypothesis-driven questions on the function of endocannabinoid signaling, which has culminated in a paradigm shift in neuroscience.
While anterograde synaptic transmission has been extensively studied for decades, much less information was known about retrograde signaling pathways at chemical synapses. Several candidates such as gases (e.g. nitric oxide), peptides (e.g. dynorphin), growth factors (e.g. brain-derived neurotrophic factor) or even conventional amino acid transmitters such as glutamate or GABA were shown to be released by the somatodendritic domain of postsynaptic neurons and then to act on the axon terminals of presynaptic neurons (Regehr et al., 2009). However, most of these retrograde messengers operate at specific synapses or restricted to a few cell types, and none of them could fully explain most common forms of retrograde synaptic communication. Based on high anandamide synthase activity in the hippocampus and the then prevailing view that the chemically related lipid molecule arachidonic acid is a retrograde messenger in hippocampal long-term potentiation (Williams et al., 1989), Devane and Axelrod proposed first that anandamide may also play a retrograde messenger role on axonal CB1 receptors (Devane and Axelrod, 1994). In accordance, the first immunohistochemical studies visualizing CB1 protein localization reported dense meshwork of fibers throughout the brain at the light microscopic level (Egertova et al., 1998; Tsou et al., 1998). These fibers proved to be axons in both the rat and human brain, as revealed by high-resolution immunogold staining and electron microscopy (Katona et al., 1999; Katona et al., 2000). In fact, the majority of CB1 receptors accumulated presynaptically on axon terminals of GABAergic interneurons in the hippocampus (Fig. 2A). Furthermore, CB1 receptor agonists reduced electrically-evoked GABA release (Fig. 2B), in accordance with a proposed retrograde messenger function of endocannabinoid signaling (Katona et al., 1999). The presynaptic localization of CB1 receptors and its inhibitory effect on neurotransmitter release have proved to be a general feature of most axon terminals in the central (Kano et al., 2009), and peripheral nervous system (Vizi et al., 2001).
The Retrograde Route Of Endocannabinoid Signaling In The Brain
The most important support for the retrograde scenario came subsequently from the study of an electrophysiological paradigm, in which selective depolarization of a postsynaptic neuron induces short-term depression of GABA release from axon terminals innervating the same postsynaptic neuron (DSI) (Llano et al., 1991; Pitler and Alger, 1992). This robust phenomenon premised the existence of a bona fideretrograde messenger, and thus, the demonstration that three independent antagonists of CB1 receptors block DSI at hippocampal GABAergic synapses (Fig. 2C-D) (Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001), together with the presynaptic localization of CB1 receptors (Katona et al., 1999), were in agreement with the plausible scenario that endocannabinoids may be the long-awaited retrograde messengers. Importantly, depolarization-induced suppression of excitation (DSE) was also inhibited by a CB1 antagonist at cerebellar excitatory synapses (Kreitzer and Regehr, 2001). Several other forms of synaptic plasticity were subsequently reported to be CB1-dependent including e.g. long-term depression (Fig 2E-F) (Gerdeman et al., 2002; Marsicano et al., 2002; Robbe et al., 2002). Collectively, these findings indicated that endocannabinoid signaling plays a conceptually similar role at distinct types of synapses throughout the brain, and represent the turning point, when endocannabinoid research finally became a major focus for mainstream neuroscience.
Although the most parsimonious scenario is the retrograde route for endocannabinoids, the manner of how anandamide and/or 2-AG get through the extracellular space is still an unresolved issue considering that these lipid messengers are fairly hydrophobic with logP values of 5.1 and 5.39 for anandamide and 2-AG, respectively (Maccarrone, 2008). Nevertheless, converging evidence from the combination of biochemical, anatomical, pharmacological and physiological experiments fully supports the retrograde scenario. As the first step, molecular identification of enzymes involved in endocannabinoid metabolism helped to define which endocannabinoid molecule is responsible for given forms of endocannabinoid-mediated plasticity. For example, the inactivation of anandamide is carried out by a serine hydrolase called fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996). Thus, the lack of effect of FAAH inhibitors in a given paradigm indicates that anandamide is not involved in that particular phenomenon as it was stated for example for hippocampal DSI (Kim and Alger, 2004). The second candidate 2-AG is synthesized by two isoforms of diacylglycerol lipase, α and β, (Bisogno et al., 2003), whereas a monoacylglycerol lipase (MGL) was found to degrade the majority (85%) of 2-AG in the brain (Dinh et al., 2002; Blankman et al., 2007). Genetic inhibition of MGL consistently enhanced short-term synaptic depression (Pan et al., 2011; Straiker et al., 2011), whereas genetic inactivation of DGL-α fully eliminated all forms of endocannabinoid-mediated synaptic plasticity in the prefrontal cortex (Yoshino et al., 2011), hippocampus (Gao et al., 2010; Tanimura et al., 2010), striatum and cerebellum (Tanimura et al., 2010). Thus, the indispensable involvement of DGL-α and the regulatory role of MGL in short-term synaptic depression clearly supports the view that 2-AG is the enigmatic synaptic endocannabinoid.
However, these pharmacological and genetic perturbations would not exclude a scenario that 2-AG plays an autocrine role on axon terminals, where CB1 receptors are located. The additional support derives from anatomical observations, which revealed that the subcellular segregation of endocannabinoid-metabolizing enzymes paves a retrograde way for 2-AG throughout the brain. DGL-α was found postsynaptically at several synapse types in the spinal cord (Nyilas et al., 2009), cerebellum (Yoshida et al., 2006), ventral tegmental area (Mátyás et al., 2008), striatum (Uchigashima et al., 2007), basolateral amygdala (Yoshida et al., 2011), hippocampus (Katona et al., 2006; Yoshida et al., 2006), prefrontal cortex (Lafourcade et al., 2007) and even in the human hippocampus (Ludányi et al., 2011). Conversely, MGL was observed presynaptically in axon terminals throughout the brain (Gulyás et al., 2004; Ludányi et al., 2011; Uchigashima et al., 2011 Yoshida et al., 2011). Taken together, these anatomical and physiological experiments outlined that the most parsimonious scenario for retrograde synaptic signaling involves 2-AG, which is synthesized and released postsynaptically and then acts on CB1 receptors located on nearby presynaptic axon terminals.
In their influential review, Sudhof and Malenka recently argued that one of the most important advances in our understanding of synaptic transmission in the last 20 years was the discovery that endocannabinoids are the principal mediators of retrograde synaptic communication (Sudhof and Malenka, 2008). Since the breakthrough discoveries ten years ago, several hundred studies have dealt with the role of endocannabinoids in synaptic transmission and the retrograde scenario has become widely accepted. It is vital in most biological signaling systems that information flow is precisely controlled by feed-back mechanisms. Thus, it is not surprising that synaptic transmission in chemical synapses requires a similar feed-back mechanism, although it was clearly unforeseen that the consensus molecule for this function would be an endocannabinoid. Also unexpected was that the basic operational principles of retrograde endocannabinoid signaling have so many features in common with conventional anterograde synaptic transmission. In the following sections, we aim to highlight the striking conceptual similarities between classical amino acid transmitter-mediated neurotransmission and retrograde endocannabinoid signaling arguing that the endocannabinoid system is a component of chemical synapses as basic as the conventional neurotransmitter systems (Table 1). It is impossible in a single review to detail these biological phenomena, hence, we picked a few notable examples to summarize key features of endocannabinoid signaling together with some physiological and pathophysiological implications focusing on burning questions in endocannabinoid research.
Analogies can be observed in many respects between anterograde transmission mediated by classical amino acid transmitters and endocannabinoid-mediated retrograde signaling. See main list for abbreviations.
Why the brain needs – at least – two endocannabinoid molecules? Neurons exploit several messengers to operate anterograde synaptic transmission in the brain, predominantly the classical amino acids glutamate and GABA, but glycine and the aromatic amino acid derivative monoamines such as dopamine, serotonin or noradrenaline have also important functions. As retrograde messenger, 2-AG is the key player in most forms of homo- and heterosynaptic short-term depression and in some forms of long-term depression (Heifets and Castillo, 2009; Kano et al., 2009). It is clear however that anandamide also acts through CB1receptors in several neurobiological paradigms (Kinsey et al., 2009; Clapper et al., 2010; Straiker et al., 2011), where it may function as a retrograde synaptic messenger and mediate certain forms of synaptic homeostasis and plasticity in presynaptic CB1 receptor-dependent manner (Gerdeman et al., 2002, Kim and Alger, 2010). Alternatively, anandamide’s synaptic function can also be the activation of postsynaptic TRPV1 receptors (Chavez et al., 2010; Grueter et al., 2010). The division of labor between anandamide and 2-AG may be reflected in spatial segregation, if anandamide and 2-AG serve as messengers at different synapses, in distinct microcircuits, or in separate brain regions. This is supported by observations that specific FAAH and MGL inhibitors recapitulate only subsets of behavioral components of cannabinoid effects in vivo (Long et al., 2009a). These behaviors are regulated by CB1 receptors located in distinct cell types and brain circuits (Monory et al., 2007), and spatial isolation also occurs at the subcellular level, because MGL and FAAH are segregated into the presynaptic and postsynaptic domains of neurons, respectively (Gulyás et al., 2004). The division of labor may also happen at different time scales. Phasic endocannabinoid signaling, such as DSI is mediated by 2-AG (Kim and Alger, 2004, Tanimura et al., 2010), whereas tonic endocannabinoid signaling involves the mobilization of both 2-AG (Hashimotodani et al., 2007) and anandamide (Kim and Alger, 2010) at hippocampal GABAergic synapses, though likely under different physiological conditions. Finally, the two signaling systems may even interplay in certain behavioral processes. Neither FAAH, nor MAGL inhibitors alone could recapitulate catalepsy or drug discrimination, typical CB1 agonist-evoked behavioral effects. However, a dual FAAH/MGL inhibitor produces catalepsy and also Δ9-THC-like drug discrimination response (Long et al., 2009b). Thus, the combined action of 2-AG and anandamide may be required to fully engage CB1 receptors at specific synapses, and if the mobilization of two messenger molecules require different physiological signals, then presynaptic CB1 receptors may operate as coincidence detectors to underlie synaptic plasticity analogously as postsynaptic NMDA receptors.
The level of complexity in the operational principles and functional significance of retrograde endocannabinoid signaling is further increased by the emerging concept that, in contrast to the primarily amino acid-based anterograde transmission, a multifaceted lipid signaling system evolved to fulfill the complex physiological tasks reliant on retrograde signaling. For example, both anandamide and 2-AG are oxygenated by cyclooxygenase-2 (COX-2) at postsynaptic sites (Yu et al., 1997; Kozak et al., 2000; Kim and Alger, 2004; Straiker et al., 2011). The resulting prostanoids, e.g. prostaglandin E2 glycerol ester (PGE2-G) increase neurotransmitter release from axon terminals (Yang et al., 2008), which is the opposite effect to that of 2-AG. Thus, COX-2, which is transported to synapses in an activity-dependent manner may be an important molecular switch to change the direction of synaptic plasticity. Therapeutically important in vivo manifestation of this phenomenon occurs in supraspinal and spinal pain circuitries, where 2-AG has an overall anti-nociceptive effect (Hohmann et al., 2005; Nyilas et al., 2009), whereas 2-AG-derived PGE2-G causes hyperalgesia (Hu et al., 2008). Remarkably, the highly potent analgesic effects of nonsteroidal anti-inflammatory drugs (NSAIDs) like paracetamol (acetaminophen), a selective COX-2 inhibitor (Hinz et al., 2008), or ibuprofen, a potent inhibitor of 2-AG oxidation by COX-2 (Prusakiewicz et al., 2009) require the activation of CB1 receptors (Ahn et al., 2007; Telleria-Diaz et al., 2010). Thus, these NSAIDs may partially exhibit their analgesic effects via vetoing the metabolism from anti-nociceptive 2-AG to hyperalgesic prostaglandin caused by hyperalgesia-induced elevations in COX-2 activity.
The discovery of 2-epoxyeicosatrienoylglycerols (2-EGs) also revealed a link to lipoxygenase and cytochrome P450 pathways. These novel lipids are present in the brain (especially 2-11,12-EG) and surprisingly, they are potent endogenous ligands of both cannabinoid receptors in vivo (Chen et al., 2008). Anandamide can be transformed to 5′,6′-epoxyeicosatrienoic acid by CP450 epoxygenases, and activates TRPV4 channels at submicromolar concentrations (Watanabe et al., 2003a), whereas the related eicosanoid 12-(S)-hydroperoxyeicosatetraenoic acid is the retrograde mediator of TRPV1-dependent long-term depression at hippocampal Schaffer collateral-interneuron synapses (Gibson et al., 2008). Although the puzzling question, why lipids are utilized so extensively as retrograde messengers in contrast to the predominantly amino acid-based anterograde transmitters may not be easy to answer, this perplexing diversity of lipid signaling pathways should definitely be in focus for neuroscience.
A striking example of parsimony in biology is the way in which neurons exploit amino acids (like glutamate or glycine) as neurotransmitters, which are otherwise basic building blocks of proteins. These amino acids can even be metabolized to each other to produce additional messengers, as GABA is synthesized from glutamate by decarboxylation. This parsimony is also shared by the endocannabinoid system. Glycerol, ethanolamine and arachidonic acid are at the crossroads of several metabolic pathways, included in several major components of biological membranes or provide energy for cellular functions. Arachidonic acid, the common constituent of 2-AG and anandamide is a conditionally essential n-6 polyunsaturated fatty acid (n-6 PUFA) and makes up a significant fraction of brain lipids (Rapoport, 2008). It is present in the diet together with its precursor linoleic acid, and consequently, when their dietary concentrations are increased, anandamide and 2-AG levels also increase (Watanabe et al., 2003b). Remarkably, this has an impact on synaptic endocannabinoid signaling, because changing the dietary n-6/n-3 PUFA ratio abolishes endocannabinoid-mediated LTD in the prefrontal cortex and nucleus accumbens (Lafourcade et al., 2011). Although the underlying mechanistic process is not fully understood, chronic elevation of 2-AG levels also disrupts CB1-mediated signaling highlighting the importance of precise metabolic regulation of 2-AG levels in the brain (Chanda et al., 2010; Schlosburg et al., 2010). Anandamide and 2-AG can also be metabolized to each other like amino acid transmitters and this metabolic pathway can even be region- and subcellular domain-specific. First, anandamide levels are decreased in the hippocampus, but not in the prefrontal cortex of DGL-α knockout animals (Gao et al., 2010, Tanimura et al., 2010, Yoshino et al., 2011). Second, free arachidonic acid can be released from 2-AG by at least three serine hydrolases (Blankman et al., 2007), and one of these, α/β-hydrolase-6 (ABHD6) regulates synaptic endocannabinoid signaling in long-term depression (Marrs et al., 2010). Moreover, ABHD6 colocalizes postsynaptically in dendrites with FAAH, which conjugates ethanolamine with arachidonic acid to form anandamide (Mukhopadhyay et al., 2011).
The biogenesis of endocannabinoids is also highly complex. Anandamide and related N-acylethanolamines (NAEs) were postulated to be synthesized by at least 5 metabolic pathways. Using N-acyl-phosphatidylethanolamines (NAPEs) as precursors, the PLA route involves phospholipase A2 and lysophospholipase D (Sun et al., 2004), the PLB route includes α/β-hydrolase 4 and glycerophosphodiesterase 1 (Simon and Cravatt, 2006; Simon and Cravatt, 2008), the PLC route is mediated by a phospholipase C and protein tyrosine phosphatase type-22 (Liu et al., 2006), whereas the PLD route exploits NAPE-hydrolyzing phospholipase D (NAPE-PLD) (Okamoto et al., 2004). In addition, anandamide can be formed by conjugation of arachidonic acid and ethanolamine in brain synaptosomes (Devane and Axelrod, 1994). A most exciting question for endocannabinoid research is to understand the functional significance of this metabolic diversity. Spatial segregation of distinct anandamide- and NAE-synthesizing pathways may underlie division of labor. Indeed, while FAAH is distributed in the somatodendritic domain of neurons (Egertova et al., 1998, Gulyas et al., 2004), NAPE-PLD was found inside glutamatergic axon terminals (Nyilas et al., 2008). Another indication of functional diversity is the different kinetics of anandamide synthesis, which suggests that the PLC route may operate at a different time scale than the PLB route (Liu et al., 2008).
The biosynthesis of 2-AG may seem to be more simple, but this can be misleading. While the role of DGL-α in synaptic plasticity is unequivocal (Tanimura et al., 2010), the precursor DAG can be synthesized in several ways. The canonical pathway includes phospholipase C-βs, which hydrolyze phophatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3) and DAG (Stella et al., 1997). Most receptor-driven 2-AG synthesis may go through this route. However, PLCβ1 is not required for depolarization-induced forms of endocannabinoid-mediated synaptic plasticity such as hippocampal DSI (Hashimotodani et al., 2005). DAG-independent 2-AG biosynthesis may occur via PLA1 and lyso-PI-specific PLC activity, the latter of which is found in brain synaptosome preparations (Tsutsumi et al., 1994; Sugiura et al., 1995). Finally, brain homogenates can also synthesize 2-AG from 2-arachidonoyl-lysophosphatidic acid by an unidentified phosphatase (Nakane et al., 2002). Thus, another important task for endocannabinoid research is to dissect which biochemical pathways are responsible for 2-AG mobilization at given locations in neuronal networks and to identify which physiological or pathophysiological stimuli activate these pathways.
A spatial segregation indicating functional division of labor has already been reported for the two isoforms of DGL (Bisogno et al., 2003). While DGL-α is found in the plasma membrane (Katona et al., 2006, Yoshida et al., 2006; Jung et al., 2011), DGL-β is restricted to intracellular membrane segments, including peri-nuclear lipid droplets (Jung et al., 2011). This spatial segregation suggests that DGL-α may play a role in intercellular 2-AG signaling, whereas DGL-β has an intracellular function. In parallel, basal 2-AG levels in the brain of DGL-α knockout mice were dropped by 80%, but remained unaffected or only partially reduced in DGL-β knockout mice (Gao et al., 2010, Tanimura et al., 2010). In contrast to DGL-α knockout mice, synaptic endocannabinoid signaling was not impaired by genetic inactivation of DGL-β (Gao et al., 2010; Tanimura et al., 2010). It is interesting to note that neurite outgrowth triggered by overexpression of DGL-α could be blocked by a CB1 receptor antagonist, whereas neuritogenesis induced by overexpression of DGL-β was CB1 receptor-independent (Jung et al., 2011). Similarly, adult neurogenesis is impaired in DGL-α, but not in DGL-β knockout mice (Gao et al., 2010).
The convincing demonstration that DGL-α is indispensable for various forms of retrograde synaptic signaling (Tanimura et al., 2010) calls for investigations of how this important enzyme is integrated into neuronal operations. At hippocampal glutamatergic synapses, DGL-α accumulates around the postsynaptic density at the edge of synapses (Katona et al., 2006; Yoshida et al., 2006). Group I mGlu receptors are located within the same perisynaptic annulus (Lujan et al., 1996) and their agonists evoke 2-AG release through the canonical Gq/11 and PLC-β pathway (Jung et al., 2005). Because both mGlu receptors and DGL-α contain binding motifs for the synaptic scaffold protein Homer (Jung et al., 2007), we proposed that they form a macromolecular complex around the postsynaptic density, the so-called perisynaptic signaling machinery (PSM), which evolved to translate excess presynaptic activity – glutamate spillover in this case – into a negative feed-back signal (Katona and Freund, 2008). Since then, new findings confirmed and extended the PSM concept. PLC-β1, another molecular constituent of this pathway was also found in the perisynaptic annulus (Fukaya et al., 2008). Moreover, the long-isoform Homer2b turned out to be necessary for mGlu-triggered 2-AG release (Won et al., 2009, Roloff et al., 2010), whereas the activity-dependent short isoform (Homer1a) dismantled the PSM and ablated this process (Roloff et al., 2010).
Importantly, DGL-α may not only function as a 2-AG-synthesizing enzyme, but could play another role in regulating DAG levels. This function may even be phylogenetically more ancient, because insects lack cannabinoid receptors, but express a DGL-α ortholog encoded by the inaE gene, which is necessary for the opening of TRP channels by DAG (Leung et al., 2008). In mammals, TRP channels like TRPC1 or TRPC3 are also known to be anchored by Homer, concentrated perisynaptically, and stimulated by DAG (Kim et al., 2003, Yuan et al., 2003). In addition, activation of TRPC channels accounts for group I mGlu receptor-triggered feed-forward enhancement of excitability of postsynaptic neurons (Kim et al., 2003; Hartmann et al., 2008). Taken together, some molecular players within the PSM are primarily responsible for feed-forward excitation. However this signal is controlled by DGL-α, which may act as a molecular switch by transforming a feed-forward excitatory DAG signal into a negative feed-back signal via 2-AG (Fig. 3). Perisynaptic metabotropic glutamate receptors cannot be activated by single synaptic volleys as intrasynaptic ionotropic glutamate receptors, but require elevated, usually bursting presynaptic population activity (Tempia et al., 1998; Fan et al., 2010). Therefore, we propose that the essential physiological function of the PSM domain of excitatory synapses is to monitor the magnitude of presynaptic activity. Increased presynaptic activity may need to be transformed to a feed-forward excitatory response to increase the excitability of the postsynaptic neuron and to support synaptic potentiation. However, excess presynaptic activity can also become pathological, hence efficient negative feed-back mechanisms should kick in. We suggest that DGL-α may be involved in this mechanism in a strikingly parsimonious manner by terminating feed-forward excitation and initating feed-back inhibition, in other words, by eliminating the cause and the consequence of the excess presynaptic activity at the same time (Fig. 3A-B).
DGL-α As A Molecular Switch Between GPCR-Mediated Feed-Forward Excitation And Feed-Back Inhibition
We recently termed the second, 2-AG leg of the pathway a “synaptic circuit-breaker” to indicate that this process may not only happen at single synapses in a homosynaptic manner, but may be a general network mechanism that has a pivotal role in regulating the overall level of network excitability under pathophysiological conditions with an excess glutamatergic tone (Katona and Freund, 2008). Neuronal insults e.g. convulsions or closed-head injury evoke 2-AG release (Panikashvili et al., 2001; Wettschureck et al., 2006), whereas perturbations of the synaptic circuit-breaker leads to reduced seizure thresholds and increased incidence of epileptic seizures. Double Gq/11 and PLC-β1 knockout animals die at a young age as a result of spontaneous seizures (Kim et al., 1997; Wettschureck et al., 2006), whereas glutamatergic cell-specific overexpression or deletion of CB1 receptors are protective or convulsive, respectively (Marsicano et al., 2003; Monory et al., 2006; Guggenhuber et al., 2010). Finally, breakdown of the circuit-breaker also occurs in human patients with chronic, intractable temporal lobe epilepsy, whose hippocampus has reduced levels of DGL-α and CB1 receptors (Ludányi et al., 2008). Taken together, the significance of the PSM and retrograde 2-AG signaling is also reflected at the pathophysiological level and may be exploited for therapy in the future.
A salient emerging concept is that the PSM at glutamatergic synapses may only be a specialized case of a much more fundamental cell physiological mechanism involving the same macromolecular complex and retrograde endocannabinoid signaling. Following the initial observations that Gq/11-coupled, postsynaptic mGlu1 and mGlu5 receptors can elicit synaptic endocannabinoid signaling in the cerebellum and hippocampus (Maejima et al., 2001; Varma et al., 2001), at least 16 other neurotransmitter molecules were shown to trigger 2-AG release and CB1 receptor activation via Gq/11-coupled receptors, PLC-β and DGL-α (Fig 3). Notably, besides the homosynaptic feed-back processes, upstream activation of this macromolecular complex can often lead to heterosynaptic depression of the release of another neurotransmitter as is the case for serotonin and 5HT2A/5HT2B/5HT2C receptors in the inferior olive and elsewhere (Parrish and Nicolls, 2006; Best and Regehr, 2008). These signalosomes may not always be restricted to the perisynaptic zone of synapses, but their subcellular location reflects the source and chemical nature of the given transmitter. For example acetylcholine, which primarily reaches its receptors by volume transmission can evoke endocannabinoid signaling in several brain regions through M1receptors, which are distributed throughout the somatodendritic surface of postsynaptic neurons (Kim et al., 2002; Uchigashima et al., 2007; Yamasaki et al., 2010). Some of these signaling mechanisms can be surprisingly cell type-specific as has been shown for the neuropeptide cholecystokinin and CCK2 receptors in the hippocampus (Lee and Soltesz, 2011; Lee et al., 2011). Some may convey information about the general physiological or metabolic state of the animal like the wake-promoting peptide orexin-B and its Gq/11-coupled receptors OX1 and OX2 (Haj-Dahmane and Shen, 2005), endothelin-1 and its ETA receptor (Zampronio et al., 2010), oxytocin and its OT receptor (Oliet et al., 2007) or ghrelin and its receptor (Kola et al., 2008), and then regulate feed-back hormonal responses via the modification of synaptic weights in subcortical and cortical circuits. Particularly interesting is how these signalosomes may be involved in pathophysiological processes upon CNS injury. Thrombin-induced arachidonic acid release led to the original discovery of a PLC-DGL pathway (Bell et al., 1979), and thrombin regulates GABAergic synaptic currents through PAR-1 receptors and retrograde 2-AG signaling in the hippocampus (Hashimotodani et al., 2011). Other functionally related pathways also stimulate endocannabinoid signaling as has been demonstrated for thromboxane A2 via the prostanoid receptor TP (Rademacher et al., 2005), and for the platelet-activating factor through its receptor PAF (Berdyshev et al., 2001). Some other GPCR-endocannabinoid signalosomes are also expected to be found in the CNS, as they are widely distributed throughout the body such as angiotensin II and its AT1 receptor (Turu et al., 2009), the bombesin’s neuromedin B, gastrin-releasing peptide and its BB1/BB2/BB3 receptors (Shimizu et al, 2011), bradykinin and its B1 and B2 receptors (Turu et al., 2009), noradrenaline and the adrenoceptors α1A α1B α1D (Turu et al., 2009) and vasopressin and its V1A and V1B receptors (Turu et al., 2009). It may be too early to claim that the DGL-α – 2-AG – CB1 (and maybe also CB2) endocannabinoid signaling pathway is a built-in feature of the downstream signaling pathway upon Gq/11-coupled receptor activation, nevertheless, when present, it can efficiently translate a feed-forward signal into a feed-back signal to regulate cellular functions.
As a conceptual similarity again with classical amino acid transmitters, which act on several ionotropic (AMPA, NMDA, kainate or GABAA, GABAC and Gly) and metabotropic (mGlu or GABAB) receptors to accomplish their diverse responsibilities, these lipid messengers can also interact with several other molecular targets besides CB1 and CB2 cannabinoid receptors. Among these potential targets are ligand-gated ion channels like 5-HT3, glycine and nicotinic acetylcholine receptors, non-selective cation channels like TRPV1, TRPA1 or TRPM8, voltage-gated ion channels like T-type calcium channels or the TASK potassium channels, and metabotropic receptors like GPR55 (for review see Pertwee et al., 2010). An especially exciting research direction is to delineate the neurobiological significance of these interactions, which, despite some promising progress (Chavez et al., 2010; Grueter et al., 2010), is largely unknown (Pertwee et al., 2010).
An additional level of signaling complexity for anterograde transmission comes from the variable subunit compositions of amino acid receptors, some well-known examples of which are the synapse-specific segregation of calcium-permeable AMPA receptors determined by absence of the GluR2 subunit (Tóth and McBain, 1998), or the observation that tonic and phasic modes of GABA signaling are mediated by GABAA receptors with different subunit compositions (Glykys and Mody, 2007). A potential mechanism to increase the complexity of endocannabinoid signaling may be the phenomenon of receptor heteromerization. Heterodimers of CB1 receptors have been observed for example with D2 dopamine receptors (Kearn et al., 2005), μ-opioid receptors (Rios et al., 2006) or OX1 orexin receptors (Ellis et al., 2006). Heteromerization may impact ligand sensitivity, downstream signaling and even compartmentalization of a given receptor, which all contribute to the ultimate physiological role of the receptor complex. Thus, it will be a very important task to exploit the latest available microscopy techniques offering appropriate spatial resolution like super-resolution microscopy to characterize the cell type- and synapse type-specific distributions of given cannabinoid receptor heterodimers in brain circuits.
It is widely accepted that besides their primary ligands, the activity of most receptors is controlled by endogenous allosteric modulators. Some famous examples for glutamate receptors include the role of glycine or D-serine in the regulation of NMDA receptors (Johnson and Ascher, 1987; Kleckner and Dingledine, 1988), or the profound impact of neurosteroids on δ-subunit-containing GABAA receptors (Stell et al., 2003). Similar endogenous modulators for cannabinoid receptors are just starting to appear. The lipid virodhamine was the first reported endogenous antagonist of CB1 receptors, which surprisingly acts as an agonist on CB2 receptors (Porter et al., 2002). An unexpected new family of CB1 receptor modulators comprises the hemoglobin-derived nonapeptide hemopressin and its longer congeners, which act as an inverse agonist or agonist, respectively (Heimann et al., 2007; Gomes et al., 2009). The potential presence of allosteric binding sites on CB1 receptors and the design of selective agents targeting these sites would be especially advantageous, because full agonists evoke robust internalization of cannabinoid receptors (Jin et al., 1999), which lead to in vivo tolerance (Tappe-Theodor et al., 2007), and renders pharmacological exploitation difficult. On the other hand, internalization of presynaptic CB1 receptors on axon terminals offers a new level of physiological control (Coutts et al., 2001), whereby the efficacy of endocannabinoid-mediated synaptic plasticity can be dynamically adjusted in an activity-dependent manner. Besides internalization, lateral movement of CB1 receptors on the surface of axon terminals is also well-suited to regulate CB1 receptor availability and desensitization (Mikasova et al., 2008). Notably, lateral mobility and internalization of postsynaptic AMPA receptors are also key underlying mechanisms for experience-dependent plasticity of anterograde excitatory synaptic transmission (Newpher and Ehlers, 2009).
Probably the most spectacular evidence for the profound neurobiological significance of endocannabinoid signaling is the wide repertoire of synaptic physiological processes which are mediated by endocannabinoids. It is again conceivable to suppose that nature followed the same rule of parsimony just as for glutamatergic and GABAergic neurotransmission by adapting the activity of the same conserved molecular players throughout the central and peripheral nervous system to accomplish so many different synaptic physiological tasks for the proper operation at the brain circuit levels. It is out of the scope of this work to summarize the hundreds of studies describing the specific function of retrograde endocannabinoid signaling from the spinal cord to the neocortex, but we recommend two excellent reviews for further reading (Heifets and Castillo, 2009; Kano et al., 2009). Instead, we aim to illustrate with a few select examples the conceptual similarities in which the brain exploits endocannabinoids for retrograde signaling processes, whereas classical amino acid transmitters for anterograde communication.
Regarding the two major modes of endocannabinoid signaling, one has to differentiate between tonic and phasic actions. Just as ambient GABA has a crucial role in establishing the excitability of postsynaptic neurons through extrasynaptic GABAA receptors (Glykys and Mody, 2007), the pivotal role of ambient extracellular endocannabinoid concentrations in the determination of neurotransmitter release probability has just begun to unfold. Paired recordings from a special subtype of GABAergic interneuron and postsynaptic CA3 pyramidal neurons in the hippocampus revealed that tonic endocannabinoid signaling can mute GABA release from axon terminals through CB1 receptor activation (Losonczy et al., 2004). Subsequent research has shown that this phenomenon is not due to the constitutive activity of CB1receptors per se, but depends on the constitutive release of endocannabinoids from the postsynaptic neuron, as postsynaptic BAPTA chelation of intracellular Ca2+ signals abolished the tonic endocannabinoid signaling (Hentges et al., 2005; Neu et al., 2007). Remarkably, tonic endocannabinoid signaling is also cell type-specific. It can depend on the type of the postsynaptic neuron, e.g. proopiomelanocortin (POMC) neurons, but not the neighboring non-POMC neurons, release endocannabinoids constitutively and regulate their incoming GABAergic inputs in the arcuate nucleus of the hypothalamus, although both cell populations could produce endocannabinoids in a stimulation-dependent manner (Hentges et al., 2005). Alternatively, the same postsynaptic neuron can also regulate GABAergic inputs in a different manner as has been elegantly demonstrated in the hippocampus, where CA1 pyramidal neurons regulate perisomatic inhibition via endocannabinoids both in a tonic and phasic manner, whereas only phasic endocannabinoid signaling was found at dendritic inhibitory inputs (Lee et al., 2010). This latter observation at unitary connections also confirms that even constitutive endocannabinoid release can act in a homosynaptic and subcellularly restricted manner (Neu et al., 2007; Lee et al., 2010). Tonic endocannabinoid signaling may involve both anandamide and 2-AG, although probably at different time scales (Hashimotodani et al., 2007; Kim and Alger, 2010). The presence of tonic endocannabinoid control of neurotransmitter release indicates that physiological signals must exist to override it whenever necessary. On the other hand, this phenomenon can also serve to integrate the efficacy of a dedicated unitary connection into network activity, because high-frequency firing of the presynaptic neuron can eliminate the tonic endocannabinoid blockade (Losonczy et al., 2004; Foldy et al., 2006).
Salient features of synaptic endocannabinoid signaling ideally support the induction of changes in synaptic strength in a phasic, activity-dependent manner. The governing rules for these retrograde forms of synaptic plasticity also follow similar logic, and these mechanisms are nicely integrated into several well-known forms of anterograde synaptic plasticity mediated by glutamate or GABA. Homosynaptic short-term synaptic depression of excitation and inhibition was the first described form of endocannabinoid-mediated synaptic plasticity (Kreitzer and Regehr, 2001; Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001), and supposed to be mediated predominantly by 2-AG (Hashimotodani et al., 2007; Gao et al., 2010; Tanimura et al., 2010; Yoshino et al., 2011). Although the extracellular spread of endocannabinoids is limited (Wilson and Nicoll, 2001), endocannabinoid-mediated short-term depression is also involved indirectly in heterosynaptic forms of plasticity (Lourenco et al., 2010). Endocannabinoid-mediated forms of long-term depression were first described in the dorsal and ventral striatum and in the amygdala, but are also present at most synapses in the brain (Gerdeman et al., 2002; Marsicano et al., 2002; Robbe et al., 2002, Heifets and Castillo, 2009; Kano et al., 2009). A special, potentially homosynaptic form is the so-called spike timing-dependent long-term depression, which was described first in the neocortex and requires presynaptic NMDA or postsynaptic mGlu receptors (Sjostrom et al., 2003; Nevian and Sakmann, 2006). Heterosynaptic forms of long-term depression are also known to exploit endocannabinoids (Chevaleyre et al., 2003).
Another special form of synaptic plasticity serves to re-adjust synaptic gain in response to persistent changes of neuronal activity. This phenomenon of synaptic homeostasis involves increase in the action-potential independent release probability of glutamate and in the density of postsynaptic glutamate receptors, but also a decrease in the number of postsynaptic GABA receptors to restore circuit activity (Turrigiano et al., 2007). There are likely to be multiple forms of synaptic scaling and correspondingly, both anandamide and 2-AG was reported to contribute to homeostatic regulation of GABAergic synapses in the hippocampus (Zhang et al., 2009, Kim and Alger, 2010). In addition, just as glutamate and GABA are known to act also in an autocrine manner to regulate their own release, compelling evidence supports that both endocannabinoids may also have autocrine functions. The postsynaptic role of anandamide in long-term depression was postulated in the hippocampus and striatum (Chavez et al., 2010; Grueter et al., 2010), whereas 2-AG is the mediator of the autocrine phenomenon of slow-self inhibition in neocortical interneurons (Marinelli et al., 2008). Although it took some time for neuroscientists to accept that glutamate can also be a gliotransmitter (there are multiple types of glutamate and GABA receptors on glial cells), the idea that molecules can be utilized for multiple physiological functions gained wider recognition. In parallel, exciting new discoveries revealed that endocannabinoid signaling not only depresses, but also potentiates glutamatergic transmission via a novel form of neuron-glia crosstalk (Navarrete and Araque, 2010).
In the previous section, we aimed to illustrate the perplexing chemical and functional diversity of the endocannabinoid system in the brain and to highlight that the same neurobiological principles may govern anterograde synaptic transmission and retrograde endocannabinoid signaling. Finally, we consider the idea that subtle, but important refinements in the logic of endocannabinoid signaling were evolved to provide the most optimal contribution of retrograde communication to the functional operation of microcircuits. Probably all brain circuits require detailed studies to fully delineate how given endocannabinoid signalosomes in particular subcellular compartments mediate certain forms of synaptic plasticity and thereby regulate network activity and behavioral processes. Here we describe a few striking examples from the hippocampus (Fig. 4).
The ultimate mission of life sciences in the post-genomic era of biology is to provide a full understanding of the function of all molecular players encoded in our genome together with all small-molecule metabolites comprising our metabolome. In neuroscience, we will even need to integrate these emerging data with the cell type-catalog of the brain and functional connectomics. One admitted expectation is that these enormous datasets generated by large-scale community efforts will support systems biology approaches to uncover conceptually new principles of biology, whereas another major force fuelling these efforts is the tremendous potential for evidence-based novel therapeutics. The unfolding of the molecular, anatomical, physiological and behavioral features of endocannabinoid signaling in the last decade fully justifies this expectation, because it has led to our appreciation of the fundamental role of retrograde communication in the brain. Besides its multiple functions, molecular complexity and selective impairment in distinct brain disorders also offer hopes that the endocannabinoid system may be exploited therapeutically.